Compare Ascendis Pharma A/S (ASND) vs Atmos Energy Corporation (ATO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Atmos Energy Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Atmos Energy Corporation trades at $176.2 (market cap $29.41B). The key difference: Atmos Energy Corporation is the larger of the two by market cap, and Atmos Energy Corporation pays a 2.27% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | ATO | |
|---|---|---|
Market Cap | $17.74B | $29.41B |
Sector | Health | Utilities |
52-Week High | $277.18 | $192.25 |
52-Week Low | $163.32 | $154.10 |
Enterprise Value | $18.11B | $38.91B |
Dividend Yield | — | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Atmos Energy (ATO) trades at $176.2, up 0.85% today, with a neutral technical signal. The stock shows strong fundamentals with revenue growth to $4.70B in 2025 and a net income margin of 27.58%. Recent Q1 2026 earnings beat expectations, and the company maintains a solid dividend. Analyst consensus is a Buy with a $189.67 price target, though technical indicators suggest near-term consolidation around key support and resistance levels.
The outlook for ATO is positive due to steady earnings growth, customer expansion, and supportive regulatory changes. Risks include high capital expenditures and exposure to energy market volatility. Institutional sentiment is bullish, with no sell ratings, positioning the stock for potential upside if operational execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →
